Dr. Abel D. Jarell, MD, FAAD
Education & Selected Honors
U.S. Military Academy, West Point, NY
Bachelor of Science in Chemistry, May 1993
-
Distinguished Cadet (top 5% in class academically)
-
Superintendent’s Award (Superior Achievement in Academics, Leadership and Physical Fitness)
-
West Point Outstanding Achievement in Mathematics Recognition Award (1990)
Harvard Medical School, Boston, MA
Doctor of Medicine, June 1998
-
Recipient of NIH Pre-doctoral Research Fellowship
-
AMA/Glaxo Welcome National Achievement/Leadership Delegate
Post-Graduation Education
Internship – General Surgery, 7/98 – 6/99
University of Washington, Department of Surgery, Seattle, WA
Residency – Dermatology, 7/06 – 6/09
Harvard Medical School, Department of Dermatology, Boston, MA
Chief Resident, 7/08 – 6/09
Fellowship – Dermatopathology, 7/09 – 7/10
University of California (UCSF), Department of Dermatopathology, San Francisco, CA
Board Certifications
Dermatology: American Board of Dermatology, 2009, Recertified 2019
Dermatopathology: American Board of Dermatology, 2010, Recertified 2019
Medical Licenses
Maine – current, active, unrestricted (MD22699)
Maryland – current, active, unrestricted (D0073683)
Massachusetts – current, active, unrestricted (235410)
New Hampshire – current, active, unrestricted (15251)
​
Selected Leadership Positions
4/2017 – 4/2020 President, New Hampshire Society for Dermatology
4/2016 – 4/2017 Secretary, New Hampshire Society for Dermatology
3/2018 – present Voting Member, Am. Acad. of Dermatology Healthcare & Finance Committee
3/2016 – present Voting Member, Am. Acad. of Dermatology, Leadership Committee
Experience & Positions Held
6/2019 – present Medical Director, Chief Investigator
ALLCUTIS Research, Inc., Center for Understanding Therapeutics in Skin
Portsmouth, NH
3/2016 – present Principal Investigator
ActivMed Practices & Research, Inc
Portsmouth, NH
3/2015 – present Dermatologist & Dermatopathologist
Northeast Dermatology Associates (NEDA)
Portsmouth, Conway & Dover, NH and Portland, ME
7/2010 – 1/2015 Assistant Professor of Dermatology & Dermatopathology
Walter Reed National Military Medical Center
Uniformed Services University of the Health Sciences
Bethesda, MD
-
Chief, Dermatopathology, Dermatology Section, Department of Medicine
-
Director, Walter Reed & Murtha Cancer Center Melanoma and Pigmented Lesion Clinic
-
Associate Program Director, Walter Reed Dermatopathology Fellowship
-
Cancer Liaison Physician for Walter Reed to the American College of Surgeons
-
Head of the Dermatology visitor, medical student and intern/resident rotators
-
Scientific Review Committee Member, Walter Reed Bethesda
-
Quality Assurance Officer, Department of Dermatology
-
Winner of 1st Place, Association of Military Dermatologists Staff Research Award (2012)
-
Winner of 3rd Place, Association of Military Dermatologists Staff Research Award (2014)
-
Delegate to the American Academy of Dermatology Academic Dermatology Leadership Program (ADLP)
8/2011 – 2/2015 Staff Dermatologist & Dermatopathologist
Saco River Medical Group
Conway, NH
Work as dermatologist and dermatopathologist in under-served White Mountains / Mt. Washington Valley region of NH. Perform all duties of general dermatologist and dermatopathologist, approximately 2 full days per month.
​
1/2011 – 6/2011 Squadron Surgeon & General Medical Officer
2nd Cavalry Regiment / 4th Squadron
Kandahar Province and Arghandab River Valley, Afghanistan
Squadron staff officer, consultant to the commander. Deployed to Afghanistan in support of Operation Enduring Freedom. Duties include overall responsibility for health and welfare of squadron and all forward operating base personnel (approx. 1,100).
7/2003 – 8/2004 Brigade Surgeon & General Medical Officer
3rd Brigade/1st Armor Division
Ft. Riley, KS
8/2004 – 5/2006 Brigade Staff Officer, Consultant to Commander
1st Brigade/1st Infantry Division
Ft. Riley, KS
Deployed to Iraq in support of Operation Iraqi Freedom. Duties include overall responsibility for health and welfare of Brigade Combat Team (approx. 4,500 soldiers), primary care medical management, preventive medicine, supervision of five physician assistants and combat readiness for brigade. Senior medical officer in combat theatre of operations, overseeing additional six physicians. Supervise technical training of medical personnel. Monitor and supervise aeromedical and ground ambulance evacuation (MEDEVAC). Recipient of the Combat Medical Badge for performance of medical duties while under fire during combat operations. Recipient of the Meritorious Service Medal and nominated for the Bronze Star Medal.
1/2001 – 7/2002 Graduate Student & Research Assistant
Neurosurgery / Neurology National Capital Neurotrauma Research Laboratory
Bethesda, MD
Laboratory of Drs. James Ecklund and Geoffrey Ling. Conducted research directed toward the elucidation of cellular and molecular mechanisms involved in traumatic brain injury.
6/1999 – 1/2001 Post-Doctoral Research Fellow
University of Washington and Children’s Hospital, Dept. of Neurological Surgery
Seattle, WA
Laboratories of Drs. Richard S. Morrison and Michael Bobola. Focus of Morrison lab is on elucidating mechanisms, modulators and effectors involved in neuronal cell death especially in oncology and programmed cell death. Investigated involvement of new gene and protein expression in variety of cell lines as well as in tumor operative specimens and modulated expression of novel gene/protein to study effects. Conducted seminal studies in novel cell cycle regulator pescadillo (gene and protein) and its involvement in tumor malignancy. Also, using gene transfection methods, investigated involvement of BAX and BAD in neuronal cell death. Focus of Bobola laboratory is pediatric neuro-oncology. Obtained pediatric brain tumor specimens and purified RNA for RT-PCR amplification of cDNA to study novel gene expression.
​
3/1994 – 4/1998 NIH Predoctoral Research Assistant
Children’s Hospital & Harvard Medical School Program in Neuroscience
Boston, MA
Laboratory of Dr. Jeffrey D. Macklis, Department of Neurology, Children’s Hospital. Primary focus of lab is on neocortical development, cellular differentiation, and neuronal transplantation. Designed and conducted experiments in conjunction with Macklis and others on C57Bl/6J mice to determine spatial and temporal characteristics of microglia in model of selective neuronal degeneration. Provided evidence for programmed cell death in the same model demonstrating the necessity for both new protein synthesis and endonuclease activation. Work presented at 1996 Society for Neuroscience Annual Meeting, 1995 & 1997 Soma Weiss Research Assemblies, and 1997 NIH Scientists, Tools & Research for the 21st Century Conference.
Principal Investigator Clinical Research Trial Experience
2015
Eli Lilly Phase 3, Moderate to Severe Plaque Psoriasis
Braintree Phase 3, Topical Treatment for Moderate to Severe Facial Acne
Cutanea Life Sciences Phase 2, Topical Gel for Females with Moderate to Severe Facial Acne
Dermira Phase 3, Moderate to Severe Plaque Psoriasis, Certolizumab Pegol
Eli Lilly Phase 3, Moderate to Severe Plaque Psoriasis, SC injection
Regeneron Phase 3, Moderate to Severe Atopic Dermatitis, Dupilumab SC injection
2016
Par Pharmaceuticals Phase 3, Mild to Moderate Atopic Dermatitis
Sol-Gel Phase 2, Topical Treatment for Facial Acne
2017
Athenex Phase 3, Topical Treatment for Actinic Keratosis
Cellceutix Phase 3, Moderate to Severe Plaque Psoriasis, Oral Treatment
Cutanea Life Sciences Phase 3, Common Warts
Foamix Phase 3, Moderate to Severe Acne
Incyte Pharmaceuticals Phase 2, Vitiligo, Topical Treatment
RXi Pharmaceuticals Phase 2, Common Warts, Samcyprone Ointment
UCB Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0009)
2018
AbbVie, Inc. Phase 3, Moderate to Severe Atopic Dermatitis in Adolescents & Adults
Asana Biosciences Phase 2, Moderate to Severe Atopic Dermatitis, Oral Treatment
Incyte Pharmaceuticals Phase 3, Atopic Dermatitis, Topical Treatment
Trevi Pharmaceuticals Phase 2b/3, Prurigo Nodularis, ER Nalbuphine
UCB Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0013)
UCB Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0014
UCB Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0015)
Asana Biosciences Phase 2b, Moderate to Severe Atopic Dermatitis, Open-Label Extension
Bristol Myers Squibb Phase 3, Moderate to Severe Plaque Psoriasis, SC injection
Celgene Corporation Phase 3, Moderate to Severe Genital Psoriasis, Oral Treatment
Dermira Phase 2b, Moderate to Severe Atopic Dermatitis, Lebrikizumab
Eli Lilly Phase 4, Moderate to Severe Plaque Psoriasis, SC injection
2019
AbbVie, Inc. Phase 3, Risankizumab Autoinjector for Psoriasis
Amgen Phase 3, Moderate to Severe Plaque Psoriasis, SC injection
Arcutis , Inc. Phase 3, Mild to Moderate Plaque Psoriasis, Topical Treatment
Asana Biosciences Phase 2, Moderate to Severe Hand Eczema
Concert Pharmaceuticals Phase 2, Moderate to Severe Alopecia Areata
Concert Pharmaceuticals Phase 2, Moderate to Severe Alopecia Areata, Open-Label Extension
Dermira Phase 3, Moderate to Severe Atopic Dermatitis, Lebrikizumab
Dermira Phase 3, Moderate to Severe Atopic Dermatitis, Lebrikizumab/Topical Combo
Dermira Phase 3, Moderate to Severe Atopic Dermatitis Adolescents, Lebrikizumab
Eli Lilly Phase 2/3, Moderate to Severe Alopecia Areata, Baricitinib
Eli Lilly Phase 1, Atopic Dermatitis, SC injection
Eli Lilly Phase 1, Psoriasis, SC injection
Galderma Phase 3b, Topical Treatment for Moderate to Severe Facial & Truncal Acne
Galderma Phase 3, Topical Treatment for Actinic Keratosis
Novan, Inc. Phase 3, Topical Treatment for Molluscum Contagiosum
UCB Phase 3, Moderate to Severe Plaque Psoriasis, Adolescent & Pediatric, Cimzia
UCB Phase 3, Moderate to Severe Hidradenitis Suppurativa, SC injection
2020
AoBiome Therapeutics Phase 2, Topical Spray for Pruritis in Adults with a History of Atopic Dermatitis
Arcutis, Inc. Phase 3, Mild to Moderate Plaque Psoriasis, Topical Treatment, Open-Label Ext
Arcutis, Inc. Phase 2b, Scalp and Body Psoriasis in Adolescents and Adults, Topical Treatment
Arcutis, Inc. Phase 2, Topical Treatment for Seborrheic Dermatitis
AstraZeneca Phase 2, Moderate to Severe Atopic Dermatitis, Benralizumab
Bellus Health Phase 2, Oral Treatment for Chronic Pruritus in Adults with Atopic Dermatitis
Bristol Myers Squibb Phase 3b, Moderate to Severe Plaque Psoriasis, SC injection, Extension Study
Dermira Phase 3, Moderate to Severe Atopic Dermatitis, Lebrikizumab Open-Label Ext
Eli Lilly Phase 2, Moderate to Severe Hidradenitis Suppurativa, SC injection
Galderma Phase 3, Topical Treatment for Actinic Keratosis, Open-Label Extension
Galderma Phase 2, Atopic Dermatitis in Adolescents and Adults, SC injection
Nimbus Lakshmi, Inc. Phase 1, Oral Treatment for Moderate to Severe Plaque Psoriasis
2021
Amgen Phase 3, Moderate to Severe Plaque Psoriasis, SC injection
AnaptysBio Phase 2, Hidradenitis Suppurativa, SC injection
AnaptysBio Phase 2, Acne Vulgaris, SC injection
UCB Phase 3, Moderate to Severe Hidradenitis Suppurativa, SC injection, Extension
​
Publications
​
Original Aticles and Case Reports
-
Gottlieb A, Gooderham M, Jarell A (2021) Absolute improvements in BSA and PASI at week 12 associate with improvements in nail psoriasis, itch, and quality of life at week 24 in treatment of moderate-to-severe psoriasis. Journal of Drugs in Dermatology. In press.
-
Jarell AD, Skenderis B, Dillon LD, Dillon K, Martin B, Quick AP, Siegal JJ, Rackley B, Cook RW (2021) The 31-Gene Expression Profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma. In Press
-
Dillon LD, McPhee M, Davidson RS, Quick AP, Martin B, Covington KR, Zolochevska O, Cook RW, Vetto JT, Jarell AD, Fleming MD (2021) Expanded evidence that the 31-Gene Expression Profile test provides clinical utility for melanoma management in a multicenter study. In press
-
Porter C, Riddle S, Jarell AD (2020) A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with or without heat-labile enterotoxin with mutation R192G. (IN PRESS) Vaccine.
-
Gutierrez R, Porter CK, Jarell AD, et al. (2020) A grading system for local skin reactions developed for clinical trials of an intradermal and transcutaneous ETEC vaccine. Vaccine. 6;38(21):3773-3779.
-
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. (2020) Br J Dermatol. 2020 Jun;182(6):1348-1358.
-
Dillon, LD, Gadzia JE, Jarell AD, et al. (2018) Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients. Skin. 2(2).
-
Wang B, Jarell AD, Bingham JL, and Bonavia GH. (2015) PET/CT Imaging of squamoid eccrine ductal carcinoma. Clin Nucl Med. 2015 Apr;40(4):322-4.
-
Hoverson K, Jarell AD, Wohltmann W. (2017) Lupus erythematosus tumidus of the scalp masquerading as alopecia areata. Cutis. 2017 February;99(2): E22-E24.
-
Morgan MK, Whitman TJ, Cohen JI, Mitchum MD, Jarell AD, Burgess TH. (2014) A patient with fever and rash. Clin Infec Dis. 2014 Jul 1;59(1):95, 136-7.
-
Oganesyan G, Jarell AD, Srivastava M, Jiang SI. (2013) Efficacy and complication rates of full-thickness skin graft repair of lower extremity wounds after Mohs micrographic surgery. Dermatol Surg. Sep;39(9):1334-9.
-
Jarell AD and McCalmont TH. (2012). Granular cell angiosarcoma. J Cutan Pathol. May;39(5):476-8.
-
Jarell AD and Mully TM. (2012) Basal cell carcinoma of the ear is more likely to be of an aggressive phenotype in both men and women. Journal of the American Academy of Dermatology. May;66(5):780-4.
-
Jarell AD, Dans MJ, Elston DM, et al. (2011) Gnathostomiasis in a patient who frequently consumes sushi. Am J Dermatopathol. Dec:33(8):91 - 93.
-
Konnikov N, Avram M, Jarell AD, Tannous Z. (2011) Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow up 12-21 months after treatment. Lasers Surg Med. Feb;43(2):72-8.
-
Morgan EA, Henrich TJ, Jarell, AD, Velazquez EF, et al. (2010) Infectious granulomatous dermatitis associated with Rothia mucilaginosa bacteremia: a case report. Am J Dermpathol. 32(2):175 – 9
-
Tucker JD, Shah S, Jarell AD, Tsai KY, Zembowicz A, Kroshinsky D (2009) Lues maligna in early HIV infection. Case report and review of the literature. Sex Transm Dis. 36(8):512 – 4.
-
Jarell AD, Hall MA, Sperling LC (2007) Uncombable Hair Syndrome. Pediatric Dermatology. 2007 Jul- Aug;24(4):436-438.
-
Jarell AD, Hall MA (2007) Swelling of the Right Ear. Am Fam Physician. 1;75(9):1379-1380.
-
Kinoshita Y, Jarell AD, Morrison RS, et al. (2001) Pescadillo, A Novel Cell Cycle Regulatory Protein Abnormally Expressed in Malignant Cells. J Biol Chem. 276(9):6656-6665.
-
Foltz, GD, Jarell AD, Schuster JS, Matsumura M, Farrell L, Nelson P, Silbergeld DL (2000) Identification and Characterization of VASP, a Motility-related Gene with Aberrant Expression in Glioblastoma. Neurosurgery. 47(2):518.
-
Kuntz C IV, Mirza SK, Jarell AD, Chapman JR, Shaffrey CI, Newell DW (2000) Type II Odontoid Fractures in the Elderly: Early Failure of Nonsurgical Treatment. Neurosurgical Focus 8(6):7 2000.
Reviews
-
Jarell AD, Kimball AB (2009 with updates in annually, most recent 2020) Rosacea. Brit Med J. Online publication.
-
Jarell AD, Lawrence D, Tsao H (2007) The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. Biologics. 1(4):407-414.
-
Temkin NR, Jarell AD, Anderson GD (2001) Antiepileptogenic Agents: How Close are We? Drugs. 61(8):1045-1055.
-
Soltesz EG, Jarell AD, Black PM, et al. (1999) Radiation Therapy for Gliomas. Crit Rev. Neurosurg. 9:376-386.
Book Chapters
-
Jepperson S and Jarell AD (2014) Ticks. Chapter in: Manual of Dermatologic Therapeutics, 8th Ed. Eds. Arndt, Hsu, Alam, et al. Lippincott.
-
Jepperson S and Jarell AD (2014) Sunburn. Chapter in: Manual of Dermatologic Therapeutics, 8th Ed. Eds. Arndt, Hsu, Alam, et al. Lippincott.
-
Kim D and Jarell AD (2014) Burns. Chapter in: Manual of Dermatologic Therapeutics, 8th Ed. Eds. Arndt, Hsu, Alam, et al. Lippincott.
-
Buikema K and Jarell AD (2014) Dermatophytosis. Chapter in: Manual of Dermatologic Therapeutics, 8th Ed. Eds. Arndt, Hsu, Alam, et al. Lippincott.
-
Jarell, AD (2012) Nodular fasciitis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 194-196.
-
Jarell, AD (2012) Proliferative myositis and proliferative fasciitis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 197-198.
-
Jarell, AD (2012) Ischemic fasciitis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 199-200.
-
Jarell, AD (2012) Postoperative spindle cell nodule. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 201-202.
-
Jarell, AD (2012) Necrotizing fasciitis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 203-204.
-
Jarell, AD (2012) Elastofibroma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 205-206.
-
Jarell, AD (2012) Desmoplastic fibroblastoma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 207-208.
-
Jarell, AD (2012) Hypertrophic scar. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 209-210.
-
Jarell, AD (2012) Keloid. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 211.
-
Jarell, AD (2012) Fibrous hamartoma of infancy. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 212-213.
-
Jarell, AD (2012) Gardner fibroma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 214-215.
-
Jarell, AD (2012) Nuchal fibroma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 216.
-
Jarell, AD (2012) Fibromatosis colli. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 217-218.
-
Jarell, AD (2012) Calcifying aponeurotic fibroma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 219-220.
-
Jarell, AD (2012) Fibroma of tendon sheath. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 221-222.
-
Jarell, AD (2012) Superficial fibromatosis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 223-224.
-
Jarell, AD (2012) Deep fibromatosis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 225-227.
-
Jarell, AD (2012) Inclusion-body fibroma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 228-229
-
Jarell, AD (2012) IgG4-related sclerosing disease. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 230-231.
-
Jarell, AD (2012) Giant cell fibroblastoma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 264-265.
-
Jarell AD, Schalock PS (2010) Procedures in Dermatologic Diagnosis and Therapy. Chapter in: Primary Care Dermatology. Eds. PC Schalock, J Hsu, and K Arndt. Philadelphia: Lipincott Williams & Wilkins. 20 – 27.
-
Jarell AD, Ecklund JM, Ling GS (2001) Traumatic Brain Injury. Chapter in: Combat Medicine. Executive Ed. GC Tsokos. New York: Humana Press. 351-370.
-
Morrison RS, Jarell AD, Schuster JM (2003) Growth Factors and Brain Tumors. Chapter in: Youman’s Neurological Surgery. 5th Ed. Executive Ed. HR Winn. Philadelphia: Saunders. 725-738.
-
Riechers RG, Jarell AD, Ling GS (2004) Infections of the Central Nervous System. Chapter in: Critical Care Neurology and Neurosurgery. Executive Ed. JI Suarez. New York: Humana Press. 515-532.
Audio Publications and Interviews
-
Jarell AD interviewed by DermTube. Shedding Light on the Darkness. DermTube video interview. Publication of the American Academy of Dermatology. July 2018.
-
Jarell AD interviewed by DermTube. Build a Better Relationship with your Dermatopathologist. DermTube video interview (https://dermtube.com/series/meeting-coverage-orlando-2017-mar/build-a-better-relationship-with-your-dermatopathologist/). Publication of the American Academy of Dermatology. March 2017.
-
Jarell AD interviewed by Kouroush AS. Help Your Dermatopathologist Work Smarter for You. Dialogues in Dermatology. Publication of the American Academy of Dermatology. April 2015.
​
Abstracts and Presentations
-
Jarell AD, Smith S, Gallo G, et al. (2021) Ixekizumab Provides More Durable Improvements in Skin Clearance, Itch, and Quality of Life than Guselkumab in Patients with Moderate-to-Severe Psoriasis: 24-week Results from IXORA-R. Congress of Clinical Rheumatology West, Sept 2021
-
Jarell AD, Smith S, Gallo G, et al. (2021) Ixekizumab Provides More Durable Improvements in Skin Clearance, Itch, and Quality of Life than Guselkumab in Patients with Moderate-to-Severe Psoriasis: 24-week Results from IXORA-R. AAD—VMX 2021
-
Jarell AD (2020) Help Your Dermatopathologist Work Smarter for You. Presented at the American Academy of Dermatology Meeting, Denver, 3/20.
-
Andrew Blauvelt A, Kempers S, Forman S, Lain E, Bruce S, Ablon G, Jarell A, Bukhalo M, Liberman R, and Fang J. Tirbanibulin, a Novel Inhibitor of Tubulin Polymerisation and Src Kinase Signalling, for Actinic Keratosis: Results from two Phase III Studies. Eur Academy of Dermatology 2020.
-
Jarell AD (2018) Shedding Light on the Darkness—Pigmented Lesions. Presented at the American Academy of Dermatology Meeting, Chicago, 7/18.
-
Jarell AD (2018) Thin and Early Stage Melanoma. Presented at the Society for Dermatology Physician Assistants Annual Meeting by invitation, Seattle, WA.
-
Jarell AD (2018) Locally Advanced and Metastatic Melanoma. Presented at the Society for Dermatology Physician Assistants Annual Meeting by invitation, Seattle, WA.
-
Jarell AD (2017) Shedding Light on the Blackness—Pigmented Lesions. Presented at the American Academy of Dermatology Meeting, New York, 7/17.
-
Jarell AD (2017) Help Your Dermatopathologist Work Smarter for You. Presented at the American Academy of Dermatology Meeting, Orlando, 3/17.
-
Brady SP and Jarell AD (2015) Strappy Cells: A distinctive histological feature of and useful diagnostic clue in chondrodermatitis nodularis helicis. Am Society of Dermatopathoology Meeting, San Francicso, 10/15.
-
Jarell AD (2014) Help your dermatopathologist work smarter for you. Podium-presented at American Academy of Dermatology Meeting, Chicago, 8/14.
-
Gutierrez R, Riddle M, Porter C, Maciel M Turiansky G, Jarell, A, Savarino S. (2013) Development and use of vaccine site grading scale for local vaccine site reactions after transcutaneous and intradermal vaccination with adhesin based ETEC vaccine candidates. Presented at the Vaccines for Enteric Diseases (VED) 2013 - Seventh International Conference, Bangkok, Thailand, 2013.
-
Bhatia A, Hsu, J, Jarell AD, et al. (2012) The Chief Academy – Building a foundation for successful chief residents Our 5-year experience & planning for the future. Presented at the Program Directors Annual Meeting, Chicago, 2012.
-
Childs JC and Jarell AD. (2012). Papillary thyroid carcinoma metastatic to the skin. Presented at National Capital Consortium Research Day Symposium, 9 April 2012.
-
Jarell AD and Mully TM. (2010) Basal cell carcinoma of the ear is more likely to be of an aggressive phenotype in both men and women. Am Soc Dermatopathol. 2010.
-
Jarell AD, Dans MJ, Elston DM, et al. (2010) Gnathostomiasis in a patient who frequently consumes sushi. International Soc Dermatopathol. 2010.
-
Jarell AD and McCalmont TH. (2010) Granular cell angiosarcoma: A rarity. Am Soc Dermatopathol. 2009.
-
Konnikov N, Jarell AD, Tannous Z (2009) Response and recurrence rates of basal cell carcinomas treated with pulsed dye laser. American Society for Laser Medicine and Surgery Annual Meeting, 2009.
-
Jarell AD, Srivastava M, Jiang B. (2007) Full thickness skin graft (FTSG) repair for lower extremity (below knee) tumors treated by Mohs Micrographic Surgery (MMS). Mohs College Annual Meeting, 2007.
-
Ling GSF, Riechers RG, Krishna PM, Blanchard J, Rosner M, Jarell AD, et al. (2002) Diagnosis of compartment syndrome using a microwave-based detector. Proceedings of SPIE -- Volume 4744.
-
Jarell AD, Agoston DV, Ling GSF (2001) Expression of Pescadillo, a Novel Cell Cycle Regulator, in the Injured Rat Brain. USUHS Neuroscience Research Day 2001. Abst.
-
Jarell AD, Foltz GD, Kinoshita Y, Morrison RS (2001) Pescadillo: Characterization of a Novel Cell Cycle Regulator Abnormally Expressed in Human Tumors. Congress of Neurological Surgeons Annual Meeting, 2001. Abst. (Recipient of CNS Overall 2nd Prize for Outstanding presentation).
-
Foltz GD, Jarell AD, Schuster J, Matsamura M, et al. (2000) Identification and Characterization of VASP, a Motility- Related Gene with Aberrant Expression in Glioblastoma, using cDNA Microarrays. Congress of Neurological Surgeons Annual Meeting, 2000. Abst.
-
Kuntz C IV, Jarell AD, Chapman JR, Shaffrey CI, Newell DW (1999) Odontoid Type 2 Fractures in the Elderly: Operative vs. Nonoperative Treatment. Assoc. of American Neurological Surgeons Annual Meeting, 2000. Abst.
-
Jaramillo AD, Leavitt BR, Macklis JD (1997) Targeted Photolytic Apoptosis in Neuronal PC12 Cells is Dependent on New Protein Synthesis and Intrinsic Endonuclease Activity. NIH Scientists, Tools, & Research for the 21st Century Abst.
-
Jaramillo AD, Leavitt BR, Macklis JD (1996) Targeted Photolytic Apoptosis in PC12 Cells is Dependent on Intrinsic Endonuclease Activity. Soc. Neurosci. Abst. 679.13.
-
Jaramillo AD, Macklis JD (1995) Spatial and Temporal Characteristics of Microglia in Model of Selective Neuronal Degeneration. Soma Weiss Abst.
-
Jaramillo AD, Sloop J (1993) Effect of Pyrazole Moiety on COS, CHO, CRL, and VERO Cell Lines. E. College Science Conf.